Because pulmonary hypertension is associated with the overexpression or activation of several RTK receptors, including those for PDGF, FGF2 and EGF, our study aimed to target the majority of these RTK receptors through Suramin treatment. This evidence concerns the gene EGF and pulmonary hypertension.